From Name:
From Email:
To Name:
To Email:

Optional Message:


High prices won't deter biotech deals

from The Wall Street Journal

The pharmaceuticals industry has entered another deal frenzy. Eye-popping price tags reflect financial pressure favoring consolidation rather than a bout of madness. Celgene announced it plans to acquire cancer specialist Juno Therapeutics for $9 billion, at a roughly 90 percent premium to Juno’s stock price before The Wall Street Journal reported a deal was close last week. more


Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063